Oriola Oyj (0NES) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and a warm welcome to Oriola's Q2 Audiocast. I am Tuas Deniosonian from Oriola's Investor Relations. With me today, I have our CEO, Katharina Gabrielsson and CFO, Mats Danielsen. In the Q and A, we will focus on questions relating to Oriola's And a recording will be available on our website later today. And before handing over to Katarina, here is the disclaimer that we all should be aware of. And now, without further ado, Katharina, please go ahead. Thank you, Tova, and welcome also on my behalf and good morning. In Oriola, we could see a positive sales development in the wholesale business in Finland during the second quarter. This is a development that we have seen since the end of last year. So I'm really pleased to see that it has continued also in the second quarter. Also the volumes in the specialty flows has been remaining on high levels and in the specialty flows, you see for example vaccine and export volumes going from Sweden as well as in Finland. We can also see that demand for Oriola's pharmaceutical distribution services was somewhat weaker than anticipated during the second quarter. The profitability landed on last year's level despite that we had higher freight costs driven by increased fuel prices. We have taken measures during the quarter to mitigate the impact more effectively going forward and especially when it comes to the fuel prices. In quarter two, the net sales was growing by 1.7 and landed on 51,800,000 Euros and adjusted EBITDA was 8,100,000 Euros which was in line with last year's level. In the supply chain, I'm pleased to see that the operations remain stable and we have made important improvements during the quarter that will make positive effects going into the second half of the year. One example is that we ha...